Shattuck Labs, Inc.
STTK evidence brief
What we can confirm
- BioSniper Score:
- 6.4 / 10
- Market Cap:
- $622.3M
- Lead Asset:
- sl-172154 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for STTK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · STTK
Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company developing potentially first-in-class monoclonal and bispecific Death Receptor 3 (DR3) blocking antibodies for inflammatory and immune-mediated diseases, with a lead program SL-325 advancing into Phase 2 trials.
Key risk: No revenue and high cash burn
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 5 clinical trials for Shattuck Labs, Inc..
Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company developing potentially first-in-class monoclonal and bispecific Death Receptor 3 (DR3) blocking antibodies for inflammatory and immune-mediated diseases, with a lead program SL-325 advancing into Phase 2 trials.
- Lead product candidate SL-325 is a high-affinity DR3 blocking antibody designed to achieve more complete blockade of the DR3/TL1A pathway than TL1A blocking antibodies [sec_mda · as of 2026-08-11].
- Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding [news · published 2026-08-11].
- Cash & equivalents were $63.3M as of 2026-06-30, with total revenue of $0.0M and net income of -$15.2M for the same period [sec].
- Accumulated deficit was $460.4 million as of June 30, 2026 [sec_mda · as of 2026-08-11].
- SL-846, an Fc-silenced, half-life extended IgG1 bispecific antibody targeting DR3 and IL-23R, is in IND-enabling studies with an IND submission expected in the first half of 2027 [sec · filed 2026-06-09].
What works
- SL-325 has a potentially best-in-mechanism immunogenicity profile and durable DR3 blockade, which may enable prolonged dosing intervals [news · published 2026-08-11].
- The company has a clear pipeline with SL-325 advancing into Phase 2b in Crohn's disease and a second Phase 2 indication in hidradenitis suppurativa, expanding beyond IBD [news · published 2026-10-01].
- SL-846 preclinical data showed equipotent or greater potency than risankizumab and icotrokinra controls in multiple assays [sec · filed 2026-06-09].
What to weigh
- The company has not been profitable since inception, with an accumulated deficit of $460.4 million as of June 30, 2026 [sec_mda · as of 2026-08-11].
- Cash & equivalents were $63.3M as of 2026-06-30, and the company expects to continue incurring significant expenses and operating losses in the near term [sec_mda · as of 2026-08-11].
- SL-325 and SL-846 are still in early clinical or preclinical stages, with no approved products or revenue [sec].
- The company has a history of pipeline changes, including prior discontinued programs (SL-279252, SL-172154) as shown in the catalyst timeline [catalyst].
From the filings
Quoted directly from source documents.
SL-325 is a high-affinity DR3 blocking monoclonal antibody designed to achieve more complete blockade of the DR3/TL1A pathway.
“SL-325 is a high-affinity DR3 blocking monoclonal antibody. DR3 is the sole known receptor for tumor necrosis factor like ligand 1A ("TL1A").”
SEC MD&A · August 11, 2026
Phase 1 data for SL-325 showed favorable safety and immunogenicity profile.
“Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding”
News · August 11, 2026
Accumulated deficit as of June 30, 2026 was $460.4 million.
“as of June 30, 2026, we had an accumulated deficit of $460.4 million”
SEC MD&A · August 11, 2026
SL-846 is an Fc-silenced, half-life extended IgG1 bispecific antibody.
“SL-846is anFc-silenced,half-life extended, IgG1 bispecific antibody.”
SEC filings · June 9, 2026
Catalyst timeline
- 2019-03-26 · Phase 1 Dose Escalation and Dose Expansion Study of SL-279252 — Historical Phase 1 start for a prior pipeline candidate (SL-279252) that was discontinued.
- 2022-03-17 · Phase 1a/1b Study of SL-172154 in MDS/AML — Historical Phase 1 start for a prior pipeline candidate (SL-172154) that was discontinued.
- 2022-08-18 · Phase 1b Study of SL-172154 in Ovarian Cancers — Historical Phase 1 start for a prior pipeline candidate (SL-172154) that was discontinued.
- 2025-11-19 · Phase 1 Study of SL-325 — Phase 1 start for the current lead candidate SL-325; data announced in June 2026.
Risks & what to watch (4)›
Key risks
- No revenue and high cash burn — Total revenue $0.0M and net income -$15.2M as of 2026-06-30; accumulated deficit $460.4M [sec][sec_mda · as of 2026-08-11].
- Early-stage pipeline dependency — Lead candidate SL-325 is only entering Phase 2; SL-846 is in IND-enabling studies; no approved products [sec_mda · as of 2026-08-11].
- Clinical trial execution risk — Phase 2b trial in Crohn's disease expected Q3 2026; delays could impact cash runway and milestones [sec · filed 2026-06-09].
- Past pipeline discontinuations — Prior programs SL-279252 and SL-172154 were discontinued, indicating historical pipeline instability [catalyst].
What to watch
- Initiation of RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease, expected in the third quarter of 2026 [sec · filed 2026-06-09].
- Safety and immunogenicity data for SL-846 from IND-enabling GLP toxicology study, expected in the second half of 2026 [sec · filed 2026-06-09].
- IND filing for SL-846, expected in the first half of 2027 [sec · filed 2026-06-09].
- Data from the 16-week treatment period of the RECEPTIVE-HS1 Phase 2 trial in hidradenitis suppurativa, expected in the first half of 2028 [news · published 2026-10-01].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Shattuck Labs, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Shattuck Labs, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.05 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
5 buys · 6 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 2.0%
- Days to cover
- 1.9
- Shares short
- 1,466,321
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
STTK short interestGovernance
Frequently asked questions
What is the AI investment thesis for Shattuck Labs, Inc.?
Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company developing potentially first-in-class monoclonal and bispecific Death Receptor 3 (DR3) blocking antibodies for inflammatory and immune-mediated diseases, with a lead program SL-325 advancing into Phase 2 trials.
What is Shattuck Labs, Inc.'s lead drug candidate?
Shattuck Labs, Inc.'s most advanced tracked candidate is sl-172154 (Phase 1) for Acute Myeloid Leukemia.
Who is the CEO of Shattuck Labs, Inc.?
Dr. Taylor H. Schreiber M.D., Ph.D. is the chief executive officer of Shattuck Labs, Inc. (STTK).
Where is Shattuck Labs, Inc. headquartered?
Shattuck Labs, Inc. (STTK) is headquartered in Austin, TX, United States.
What therapeutic areas does Shattuck Labs, Inc. focus on?
Shattuck Labs, Inc. develops therapies across Oncology, Immunology, Dermatology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.